Releases
Corporate Releases, Press Releases, and Features
Stay updated on Lundbeck’s latest company announcements. Subscribe to our releases.
LATEST RELEASES
- Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations
- Efficacy of Vyepti highlighted by new clinical trial results in severe migraine
- Lundbeck completes acquisition of Longboard
- Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled
- Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy
In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request.
More from Lundbeck
Investor Relations
Detailed information related to Lundbeck’s financial performance. Contact Palle Olesen, VP Investor Relations. + 45 3083 2426
About Us
A global pharmaceutical company specialized in brain diseases.
Press
Lundbeck seeks an open dialogue with the press. For general press enquiries, please call + 45 3643 4000